MDM2 SNP309 and Tumor Development in BRCA1 Carriers
Author Information
Author(s): Ellen R Copson, Helen E White, Jeremy P Blaydes, David O Robinson, Peter W Johnson, Diana M Eccles
Primary Institution: Cancer Research UK Oncology Unit, University of Southampton
Hypothesis
Does the MDM2 SNP309 polymorphism influence tumor development in BRCA1 mutation carriers?
Conclusion
The study found no evidence that the MDM2 SNP309 accelerates tumor development in BRCA1 mutation carriers.
Supporting Evidence
- The polymorphism was present in 58.6% of BRCA1 mutation carriers.
- No significant difference in cancer incidence was found between SNP309 carriers and wildtype individuals.
- The mean age of breast cancer diagnosis did not vary significantly with genotype.
Takeaway
This study looked at whether a specific gene change affects cancer risk in people with a certain genetic mutation, and it found that it doesn't.
Methodology
Genomic DNA was obtained from 116 BRCA1 mutation carriers and 102 healthy controls, and genotyping was performed using Pyrosequencing technology.
Limitations
The study's sample size was limited, which may affect the statistical power to detect differences.
Participant Demographics
116 BRCA1 mutation carriers (20 male, 96 female) aged 29 to 57 years; 102 healthy controls (46 male, 56 female) aged 16 to 82 years.
Statistical Information
P-Value
1.00
Statistical Significance
p = 1.00
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website